NEW YORK / Dec 06, 2023 / Business Wire / MultiPlan Corporation (NYSE:MPLN) (“MultiPlan” or the “Company”), a leading provider of technology and data-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry, today announced that Dale White, President and Chief Executive Officer, will participate in a fireside chat with investors at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 at approximately 4:30 p.m. Eastern Standard Time (EST). It is expected that industry trends and the Company’s 2023 performance will be discussed.
To listen to a live webcast of the event, please visit MultiPlan’s website or click here at least 15 minutes prior to the event to download and install any necessary audio software. Individuals who listen to the event will be presumed to have read MultiPlan’s recent filings with the Securities and Exchange Commission. Following the presentation, a webcast replay will be available for 30 days.
About MultiPlan
MultiPlan is committed to delivering affordability, efficiency, and fairness to the US healthcare system by helping healthcare payors manage the cost of care, improve their competitiveness and inspire positive change. Leveraging sophisticated technology, data analytics and a team rich with industry experience, MultiPlan interprets customers’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based and analytics-based services. MultiPlan is a trusted partner to over 700 healthcare payors in the commercial health, government, and property and casualty markets. For more information, visit multiplan.com.
Last Trade: | US$7.04 |
Daily Change: | 0.02 0.28 |
Daily Volume: | 50,075 |
Market Cap: | US$113.840M |
November 05, 2024 October 03, 2024 May 08, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB